Protracted use, up to 6 years, of an oral aminobisphosphonate in patients with established osteoporosis;Uso prolongado, hasta 6 años, de un amino-bisfosfonato oral en pacientes con osteoporosis establecida

Medicina

Volumn 57, Issue SUPPL. 1, 1997, Pages 37-44

  Zanchetta, José R ^a   Spivacow, Rodolfo F ^a   Bogado, Cesar ^a   Sarli, Marcelo ^a   Plotkin, Horacio ^a   Roldán, Emilio J A ^a  

^a Instituto de Investigaciones Metabolicas   (Argentina)

Author keywords

Fracturas esquel ticas; Osteoporosis; Pamidronato

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; DRUG EFFECT; DRUG TOLERANCE; FOLLOW UP; LONGITUDINAL STUDY; MIDDLE AGED; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; TIME;

ADMINISTRATION, ORAL; BONE DENSITY; BONE RESORPTION; DIPHOSPHONATES; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 0031311623     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Papapoulos SE, Landman JO, Bijvoet OLM, et.al. The use of bisphosphonates in the treatment of osteoporosis. Bone 1992; 13: A41-9.
2. Genant HK, Vogler JB, Block JE. Radiology of osteo-porosis. In Riggs BL, Melton LJ, (eds.), Osteoporosis: Etiology, diagnosis and management, New York: Raven Press, 1988; 181-220.
3. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Ginebra, 1994.
4. Spivacow FR, Zanchetta JR, Kerzberg EM, Frigeri A, Fiasché R, Roldán EJA. Tolerability of oral pamidronate in elderly patients with osteoporosis and other bone diseases. Curr Ther Res 1996; 57: 123-30.
5. Zanchetta JR. Plotkin H, Roldán EJA. Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance. Calcif Tissue Int 1996; 59: 70-2.
6. Frijlink WB, Te Velde J, Bijvoet OLM, Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1,1- bisphosphonate (APD). Lancet 1979; 1: 799-803.
7. Barreira JC, Messina OD, Maldonado Cocco JA, Roldán EJA. Site- dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: A preliminary report. Clin Rheumatol 1997; 16: 665.
8. Schaffler MB, Choi K, Milgrom C. Aging and matrix microdamage accumulation in human compact bone. Bone 1995; 17: 521-5.
9. Oxnard C. Bone and bones, architecture and stress, fossils and osteoporosis. J Biomechanics 1993; 26: 63-79.
10. Ferretti JL, Delgado CJ, Capozza RF, et al. Protective effects of disodium etidronate and pamidronate against the biochemical repercussion of betamethasone-induced osteopenia in growing rat femurs. Bone and Mineral 1993; 20:265 -76.
11. Melton III, LJ. Epidemiology of hip fractures: Implications of the exponential increase with age. Bone 1966; 18(supl): 121S-125S.
12. Fleisch, H. Bisphosphonates in bone disease. From the laboratory to the patient. The Parthenon Publishing Group Ltd., Carnforth, New York, 1995.
13. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333:1437-43.
14. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71.
15. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9.
16. Araujo G, Quattrocchi O, Plotkin H, Zanchetta JR, Piccinni E, Roldán E. Bioequivalence between enteric-coated pamidronate capsules and tablets. A cross-over trial in healthy volunteers. Acta Physiol Pharmacol et Therap Latino Am 1996;46:275.